SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (13208)9/29/2004 5:38:16 PM
From: Michael Young  Read Replies (1) | Respond to of 52153
 
I believe LGND has some important Phase III lung cancer results due in early 2005.

Mike



To: Icebrg who wrote (13208)10/5/2004 5:49:06 PM
From: Sam Citron  Read Replies (2) | Respond to of 52153
 
I wonder if anyone might share any comments on option valuation. CTIC March 10 Call (CUCCB) is currently trading at $1.30 while the stock is only $6.66. That seems to me to be an exceptionally handsome call premium for less than 6 month call on a stock that needs to climb 50% to come in the money.

I thought $1 was attractive price to sell these CCs, and now am amazed to see the price has risen further.

Any thoughts?

Sam



To: Icebrg who wrote (13208)10/6/2004 4:54:54 PM
From: Mao II  Read Replies (2) | Respond to of 52153
 
"....That may change of course if we see a run-up in anticipation of the results. Somehow, I doubt that though."

Why do you doubt a substantial run-up? Stellar 3 is completely blinded and date for unblinding has been substantially extended due to longer-lived patients. M2


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News